To the Editor We appreciate the clinical value of the dose-response meta-analysis performed by Leucht and colleagues.1 The interpretation provided was that doses above 5 mg/d risperidone equivalent do not provide additional protection against relapse, while the risk of relapse increases rapidly (and apparently hyperbolically) for doses less than 2.5 mg/d risperidone equivalent.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Horowitz MA, Macaulay A, Taylor D. Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia. JAMA Psychiatry. 2022;79(1):83–85. doi:10.1001/jamapsychiatry.2021.3400
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.